The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence

Gabriel Chodick, Lilac Tene, Tal Patalon, Sivan Gazit, Amir Ben Tov, Dani Cohen, Khitam Muhsen
doi: https://doi.org/10.1101/2021.01.27.21250612

Article Information

doi 
https://doi.org/10.1101/2021.01.27.21250612
History 
  • January 29, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Gabriel Chodick, PhD1,2,*,
  2. Lilac Tene, MSc1,
  3. Tal Patalon, MD1,
  4. Sivan Gazit, MD1,
  5. Amir Ben Tov, MD1,
  6. Dani Cohen, PhD#,2 and
  7. Khitam Muhsen, PhD#,2
  1. 1Maccabi Institute for Research & Innovation, Maccabi Healthcare Services, Kaufman 4, Tel Aviv Israel
  2. 2Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv Israel
  1. ↵*Corresponding Author Gabriel Chodick, PhD, Maccabi Institute for Research & Innovation, Maccabi Healthcare Services, 4 Yehezkel Kaufmann St., Tel Aviv Israel 68125, Tel: 972-50-456-1357, Email: hodik_g{at}mac.org.il, Fax: 972-73-213-2831

  1. ↵# Contributed Equally

Back to top
Posted January 29, 2021.
Download PDF
Data/Code
Email
The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence
Gabriel Chodick, Lilac Tene, Tal Patalon, Sivan Gazit, Amir Ben Tov, Dani Cohen, Khitam Muhsen
medRxiv 2021.01.27.21250612; doi: https://doi.org/10.1101/2021.01.27.21250612
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area